04:50 AM EDT, 08/01/2025 (MT Newswires) -- LENZ Therapeutics ( LENZ ) said late Thursday the US Food and Drug Administration has approved its eye drop, VIZZ 1.44%, to treat adults with presbyopia, the loss of near vision associated with aging.

The company said the product will be commercially available by mid-Q4, with US samples expected as soon as October.

The FDA decision was based on phase 3 trials in which VIZZ improved near vision within 30 minutes, the company said.

LENZ Therapeutics ( LENZ ) shares were 12.5% higher in premarket activity Friday.